GLP-1s Don't Work for Everyone: Why, and What to Do?

Why It Matters

The strategy tackles a sizable non‑responder segment, expanding therapeutic options and potentially reducing obesity‑related disease burden. It also opens a new market niche for combination regimens in a rapidly growing weight‑loss sector.

Key Takeaways

• Up to 20% of GLP‑1 users show insufficient weight loss.
• Genetics may explain variability in GLP‑1 response.
• GLP‑1 plus Contrave targets hunger and cravings simultaneously.
• Early combination therapy could prevent obesity‑related complications.
• Clinicians report better results with multi‑drug obesity protocols.

Pulse Analysis

The surge in GLP‑1 prescriptions, driven by drugs like Wegovy and Zepbound, reflects both consumer demand for rapid weight loss and insurers’ willingness to cover metabolic therapies. While average patients shed 5‑15% of their baseline weight, a notable minority—estimated at one‑in‑five—experience plateaued results despite adherence. Emerging genetic studies suggest polymorphisms in GLP‑1 receptor pathways and downstream signaling may blunt drug efficacy, prompting clinicians to seek adjunctive solutions that bypass these biological roadblocks.

Combining GLP‑1 agonists with the fixed‑dose naltrexone‑bupropion formulation (Contrave) offers a mechanistic double‑hit: GLP‑1 accelerates gastric emptying and promotes satiety, whereas Contrave modulates dopamine and opioid circuits that drive hedonic eating. Early clinical observations and the recent Obesity Science and Practice review indicate that patients previously stuck at sub‑5% weight loss can achieve additional reductions when both agents are co‑administered. The synergy appears especially pronounced in individuals with binge‑eating tendencies or pronounced food cravings, aligning with the hypothesis that addressing both homeostatic and reward pathways yields superior outcomes.

For providers, the implication is a shift toward a more nuanced, multi‑modal obesity algorithm that incorporates genetic screening, behavioral assessment, and early combination therapy. Pharmaceutical companies stand to benefit from expanded indications and co‑marketing opportunities, while payers may see long‑term cost savings as improved weight loss translates into lower incidence of diabetes, cardiovascular disease, and related complications. Ongoing trials will clarify optimal dosing schedules and safety profiles, but the current evidence positions GLP‑1 plus Contrave as a promising front‑line option for the growing cohort of poor responders.